Phytocompounds hesperidin, rebaudioside a and rutin as drug leads for the treatment of tuberculosis targeting mycobacterial phosphoribosyl pyrophosphate synthetase.

The main aim of this study is to address the global health crisis posed by tuberculosis (TB) through the exploration of novel therapeutic strategies targeting Mycobacterial phosphoribosyl pyrophosphate synthetase (MtPrsA), an untried enzyme involved in essential metabolic pathways of Mycobacterium tuberculosis. This enzyme plays a crucial role in cell wall synthesis, nucleotide biosynthesis and amino acid synthesis in M tb. Any hindrance to these may affect the growth and survival of the organism. Phytochemicals were systematically screened for potential inhibitors to MtPrsA. Subsequently, based on molecular docking studies, three compounds, namely, hesperidin, rebaudiosideA and rutin were selected. The binding stabilities of these compounds were analyzed using molecular dynamics simulation. Based on the RMSD score obtained, the binding stability of the compounds was confirmed. To validate the findings, an enzyme inhibition assay was done using recombinant MtPrsA. Ligation Independent Cloning (LIC cloning) method was used to produce recombinant His-tagged MtPrsA, followed by purification using Histrap columns. Enzyme kinetic studies unveiled the distinct modes of inhibition exhibited by each compound towards MtPrsA. RebaudiosideA and rutin emerged as competitive inhibitors, while hesperidin showcased a mixed inhibition profile. In conclusion, the study contributes valuable insights into potential therapeutic strategies for TB, through the exploration of alternative enzyme targets and the identification of phytochemical inhibitors. Notably, todate, no effective plant compounds have been reported as inhibitors to MtPrsA.